藥明康德(603259.SH):藥明一期基金擬1100萬美元認購藥明奧測1705.90萬股新股
格隆匯10月18日丨藥明康德(603259.SH)公佈,2019年10月18日,公司全資子企業WuXi PharmaTech Healthcare Fund I L.P.(以下簡稱“藥明基金一期”)、YF Digital Pathology Limited.(以下簡稱“雲鋒基金”)、LBC Sunshine Healthcare Fund L.P.(以下簡稱“清池資本”)及Mayo Collaborative Services, LLC(以下簡稱“Mayo Collaborative Services”)與藥明奧測簽署《認購協議》,藥明一期基金擬以1100萬美元認購藥明奧測新發行的1705.90萬股股份,交易完成後佔藥明奧測總股本(完全攤薄基礎上)的6.1%。
精準診斷是精準治療的基礎。本次交易是公司在大健康領域的重要投資舉措,通過投資藥明奧測,賦能精準診斷,可以進一步完善公司在大健康產業領域的佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.